Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

1.

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD; on behalf of the AIDS Clinical Trials Group Study A5202 Team.

J Antimicrob Chemother. 2014 Aug 25. pii: dku303. [Epub ahead of print]

PMID:
25159623
[PubMed - as supplied by publisher]
2.

Antiretroviral Therapy: Treatment-experienced Individuals.

Calvo KR, Daar ES.

Infect Dis Clin North Am. 2014 Sep;28(3):439-456. doi: 10.1016/j.idc.2014.06.005. Epub 2014 Jul 8. Review.

PMID:
25151565
[PubMed - as supplied by publisher]
3.

Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.

Wyatt CM, Kitch D, Gupta SK, Tierney C, Daar ES, Sax PE, Ha B, Melbourne K, McComsey GA; AIDS Clinical Trials Group Study A5224s Team.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):36-44. doi: 10.1097/QAI.0000000000000245.

PMID:
25117929
[PubMed - in process]
4.

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, Gulick RM, Na L, O'Keefe L, Robertson KR, Tierney C.

Ann Intern Med. 2014 Jul 1;161(1):1-10. doi: 10.7326/M14-0293.

PMID:
24979445
[PubMed - indexed for MEDLINE]
5.

Impaired Nef function is associated with early control of HIV-1 viremia.

Kuang XT, Li X, Anmole G, Mwimanzi P, Shahid A, Le AQ, Chong L, Qian H, Miura T, Markle T, Baraki B, Connick E, Daar ES, Jessen H, Kelleher AD, Little S, Markowitz M, Pereyra F, Rosenberg ES, Walker BD, Ueno T, Brumme ZL, Brockman MA.

J Virol. 2014 Sep 1;88(17):10200-13. doi: 10.1128/JVI.01334-14. Epub 2014 Jun 25.

PMID:
24965469
[PubMed - in process]
6.

Short communication: HIV-1 gag genetic variation in a single acutely infected participant defined by high-resolution deep sequencing.

Al-Mawsawi LQ, Wu NC, De La Cruz J, Shi VC, Wu TT, Daar ES, Lewis MJ, Yang OO, Sun R.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):806-11. doi: 10.1089/AID.2014.0097. Epub 2014 Jul 23.

PMID:
24914638
[PubMed - in process]
7.

Antiretroviral Therapy and Efficacy After Virologic Failure on First-line Boosted Protease Inhibitor Regimens.

Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS.

Clin Infect Dis. 2014 Sep 15;59(6):888-96. doi: 10.1093/cid/ciu367. Epub 2014 May 19.

PMID:
24842909
[PubMed - in process]
8.

Ineffectual targeting of HIV-1 Nef by cytotoxic T lymphocytes in acute infection results in no functional impairment or viremia reduction.

De La Cruz J, Vollbrecht T, Frohnen P, Ng HL, Daar ES, Yang OO, Lewis MJ.

J Virol. 2014 Jul;88(14):7881-92. doi: 10.1128/JVI.00482-14. Epub 2014 Apr 30.

PMID:
24789790
[PubMed - indexed for MEDLINE]
9.

Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment.

Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, Lada SM, Daar ES, Dube MP, Haubrich RH, Morris SR, Smith DM; California Collaborative Treatment Group 592 Team.

J Virol. 2014 Jul;88(14):7818-27. doi: 10.1128/JVI.00831-14. Epub 2014 Apr 30.

PMID:
24789781
[PubMed - indexed for MEDLINE]
10.

Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART.

Harezlak J, Cohen R, Gongvatana A, Taylor M, Buchthal S, Schifitto G, Zhong J, Daar ES, Alger JR, Brown M, Singer EJ, Campbell TB, McMahon D, So YT, Yiannoutsos CT, Navia BA; HIV Neuroimaging Consortium.

J Neurovirol. 2014 Jun;20(3):294-303. doi: 10.1007/s13365-014-0246-6. Epub 2014 Apr 3.

PMID:
24696364
[PubMed - in process]
11.

Impact of randomized antiretroviral therapy initiation on glucose metabolism.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, Ha B, McComsey GA.

AIDS. 2014 Jun 19;28(10):1451-61. doi: 10.1097/QAD.0000000000000266.

PMID:
24637543
[PubMed - in process]
12.

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.

Johnson DH, Venuto C, Ritchie MD, Morse GD, Daar ES, McLaren PJ, Haas DW.

Pharmacogenet Genomics. 2014 Apr;24(4):195-203. doi: 10.1097/FPC.0000000000000034.

PMID:
24557078
[PubMed - in process]
13.

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, Melbourne K, Ha B, Jahed NC, McComsey GA.

AIDS. 2013 Aug 24;27(13):2069-79. doi: 10.1097/QAD.0b013e328361d25d.

PMID:
24384588
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.

Grant PM, Tierney C, Budhathoki C, Daar ES, Sax PE, Collier AC, Fischl MA, Zolopa AR, Balamane M, Katzenstein D.

HIV Clin Trials. 2013 Nov-Dec;14(6):284-91. doi: 10.1310/hct1406-284.

PMID:
24334181
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; AIDS Clinical Trials Group 5202 Study Team.

Clin Infect Dis. 2014 Feb;58(4):555-63. doi: 10.1093/cid/cit747. Epub 2013 Nov 18.

PMID:
24253247
[PubMed - in process]
16.

Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment.

Hua X, Boyle CP, Harezlak J, Tate DF, Yiannoutsos CT, Cohen R, Schifitto G, Gongvatana A, Zhong J, Zhu T, Taylor MJ, Campbell TB, Daar ES, Alger JR, Singer E, Buchthal S, Toga AW, Navia B, Thompson PM; HIV Neuroimaging Consortium.

Neuroimage Clin. 2013 Aug 3;3:132-42. doi: 10.1016/j.nicl.2013.07.009. eCollection 2013.

PMID:
24179857
[PubMed]
Free PMC Article
17.

Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.

McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Daar ES.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):167-74. doi: 10.1097/01.qai.0000437171.00504.41.

PMID:
24121755
[PubMed - indexed for MEDLINE]
18.

Virologic correlates of anti-CMV IgG levels in HIV-1-infected men.

Gianella S, Morris SR, Tatro E, Vargas MV, Haubrich RH, Daar ES, Dube MP, Richman DD, Little SJ, Smith DM.

J Infect Dis. 2014 Feb 1;209(3):452-6. doi: 10.1093/infdis/jit434. Epub 2013 Aug 20.

PMID:
23964106
[PubMed - indexed for MEDLINE]
19.

Limited nucleotide changes in the Rev response element (RRE) during HIV-1 infection alter overall Rev-RRE activity and Rev multimerization.

Sloan EA, Kearney MF, Gray LR, Anastos K, Daar ES, Margolick J, Maldarelli F, Hammarskjold ML, Rekosh D.

J Virol. 2013 Oct;87(20):11173-86. doi: 10.1128/JVI.01392-13. Epub 2013 Aug 7.

PMID:
23926352
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment.

Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C.

AIDS. 2013 Nov 13;27(17):2725-34. doi: 10.1097/01.aids.0000432470.46379.dd.

PMID:
23921611
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk